Fothergill Annette W, Sutton Deanna A, McCarthy Dora I, Wiederhold Nathan P
Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
J Clin Microbiol. 2014 Mar;52(3):994-7. doi: 10.1128/JCM.03044-13. Epub 2014 Jan 8.
We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).
我们回顾了米卡芬净、阿尼芬净、氟康唑和伏立康唑针对念珠菌属的抗真菌药敏数据，并比较了先前和最近修订的CLSI抗真菌药敏折点所确定的耐药率。根据新的折点，米卡芬净（从0.8%增至7.6%）、阿尼芬净（从0.9%增至7.3%）和伏立康唑（从6.1%增至18.4%）针对光滑念珠菌的耐药率显著增加。氟康唑针对白色念珠菌的耐药率也有所增加（从2.1%增至5.7%）。
